Noboru Yamamoto
Overview
Explore the profile of Noboru Yamamoto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
388
Citations
5916
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Torasawa M, Yoshida T, Shiraishi K, Yagishita S, Ono H, Uehara Y, et al.
Lung Cancer
. 2025 Mar;
202:108494.
PMID: 40088580
Background: In EGFR-mutated lung adenocarcinoma (EGFRm LUAD), EGFR mutations do not necessarily result in increased EGFR expression (EGFR-exp), which differs among patients. However, the factors influencing EGFR-exp and the impact...
2.
Heymach J, Opdam F, Barve M, Tu H, Wu Y, Berz D, et al.
J Clin Oncol
. 2025 Mar;
:JCO2401727.
PMID: 40030100
Purpose: Human epidermal growth factor receptor 2 (HER2) alterations occur in many solid cancers, including non-small cell lung cancer (NSCLC). Beamion LUNG-1 (ClinicalTrials.gov identifier: NCT04886804) is assessing the safety/efficacy of...
3.
Satoh H, Okuma Y, Shinno Y, Masuda K, Matsumoto Y, Yoshida T, et al.
Lung Cancer
. 2025 Feb;
202:108453.
PMID: 40020466
Background: Advancements in pharmacotherapy, including molecular targeted therapies and immune checkpoint inhibitors, have revolutionized the treatment for Stage IV non-small cell lung cancer (NSCLC) over the past two decades. However,...
4.
Takeuchi T, Horinouchi H, Takasawa K, Mukai M, Masuda K, Shinno Y, et al.
BMC Med Inform Decis Mak
. 2025 Feb;
25(1):85.
PMID: 39962486
Background: The clinical information housed within unstructured electronic health records (EHRs) has the potential to promote cancer research. The National Cancer Center Hospital (NCCH) is widely recognized as a leading...
5.
Fujii H, Okuma Y, Hirata M, Shinno Y, Yoshida T, Goto Y, et al.
JTO Clin Res Rep
. 2025 Feb;
6(2):100691.
PMID: 39906181
Comprehensive genomic profiling (CGP) has progressed rapidly and plays an important role in advancing precision medicine in oncology. However, CGP provides opportunities for molecular-targeted therapy, but it also unveils incidental...
6.
Katsuya Y, Ikeda M, Koyama T, Sato J, Okada M, Matsubara N, et al.
Cancer Sci
. 2025 Jan;
PMID: 39832211
CBA-1205 is a novel humanized antibody targeting delta-like 1 homolog (DLK1) that enhances antibody-dependent cellular cytotoxicity activity. DLK1 overexpression has been reported in various cancer types, such as hepatocellular carcinoma...
7.
Masuda K, Yoshida T, Motoi N, Shinno Y, Matsumoto Y, Okuma Y, et al.
Thorac Cancer
. 2025 Jan;
16(1):e15529.
PMID: 39809728
Background: Schlafen 11 (SLFN-11) has been identified as a sensitizer of tumor cells to DNA-damaging agents. However, the relationship between SLFN-11 expression and clinical outcomes in patients with small cell...
8.
Tateishi A, Okuma Y, Goto Y, Arakaki M, Igawa Y, Torasawa M, et al.
Anticancer Res
. 2024 Dec;
44(12):5501-5513.
PMID: 39626947
Background/aim: Thymic carcinoma is a rare cancer with poor prognosis in unresectable cases. Treatment efficacy of carboplatin+paclitaxel (CP), lenvatinib, S-1, and sunitinib remains uncertain, with some patients experiencing increased post-treatment...
9.
Oshima T, Yamamoto S, Kawakami H, Makino T, Kawazoe A, Masuishi T, et al.
BJC Rep
. 2024 Nov;
2(1):66.
PMID: 39516370
Background: Esophageal cancer is one of the most common types of cancer in Japan. Herein, we report the efficacy and safety of E7389-LF plus the immune checkpoint inhibitor, nivolumab, from...
10.
Sato J, Sadachi R, Koyama T, Katsuya Y, Okada M, Yamamoto N
Front Med (Lausanne)
. 2024 Oct;
11:1390083.
PMID: 39380740
Background: Drug-induced lung disease (DILD) is a considerable and potentially fatal adverse event with poorly understood risk factors. Large-scale, data-driven analyses investigating regional discrepancies in DILD incidence are lacking. The...